Clinical trial
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine…
NCT00219232 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00219232 |
|---|---|
| Title | An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease |
| Official title | An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Rivastigmine Transdermal Patch |
| Enrollment | 868 |
| Start date | Feb 1, 2003 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Feb 23, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: